Company Information
Industry 制造业
Company Introduction 重庆博腾制药科技股份有限公司成立于2005年,主要为全球制药企业、新药研发机构、科研院所等提供从临床前研究直至药品上市全生命周期所需的小分子药物、多肽与寡核苷酸、生物大分子(mAb,ADC等)以及基因与细胞治疗药物的一站式定制研发和生产服务。致力于为客户提供卓越的全球化、端到端CDMO服务,让好药更早惠及大众。截至2023年6月30日,公司累计与全球800余家客户建立业务联系,拥有超2600个成功项目交付经验。我们的研发、生产、运营遍及中国(重庆、上海、四川、江苏、江西、湖北)、美国、斯洛文尼亚、比利时、瑞士和丹麦等20余个场地,拥有全球雇员5,000余人。2014年1月29日,公司股票在深圳证券交易所创业板挂牌上市。
Main Business 医药定制研发生产服务。
Legal Representative 居年丰
Top Executives
董事长:居年丰
董事:胡丽娜,薛缨,杨伟强,曹国钧
独立董事:曹国华,庞金伟,袁林
Top 5 Shareholder
Shareholder name Nature Holding Date
重庆两江新区产业发展集团有限公司流通A股14.48%30/09/2024
居年丰限售股+流通A股10.80%30/09/2024
陶荣流通A股8.11%30/09/2024
张和兵流通A股7.68%30/09/2024
中国银行股份有限公司-华宝中证医疗交易型开放式指数证券投资基金流通A股2.01%30/09/2024
Company Secretary 皮薇
Solicitors 北京市万商天勤律师事务所
Auditors 天健会计师事务所(特殊普通合伙)
Tel No 023-65936900
Fax No 023-65936901
Website www.porton.cn
Email porton.db@portonpharma.com
Company Address
Register: 重庆市(长寿)化工园区精细化工一区
Office: 重庆市北碚区云图路7号
Listing Date 29/01/2014
Shares Capital
Shares Capital: 545,464,520
Total A Share: 545,464,520
Listed A Share: 500,502,017
Non-tradable A Share: 44,962,503
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.490
DPS(RMB)* ¥ 0.487
NBV Per Share(RMB)* ¥ 10.622
Market Capitalization(RMB) 8.333B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.